Match the claim to the evidence
Start by writing down the exact claim. “Changes a hormone measurement” is a different proposition from “improves sleep,” and both differ from “reduces long-term disease risk.” Evidence for one does not automatically establish the others.
The Endocrine Society’s scientific statement on hormones and aging provides a useful framework: normal age-related endocrine changes and endocrine disease should be distinguished. A biological explanation for an age-related change is not by itself a reason to prescribe treatment.
Four questions for any study
| Question | What to look for |
|---|---|
| Who was studied? | Age, diagnosed conditions, baseline health and whether those features resemble the proposed patient population. |
| What was given? | The actual drug, route, formulation and comparator, rather than a broad category such as peptides. |
| What was measured? | A meaningful clinical outcome versus a hormone level or other intermediate measurement. |
| How reliable is the comparison? | Study design, size, duration, dropouts, adverse events and whether a control group exists. |
A citation should let you trace the claim to the research. If a sales page supplies only a study title or an unrelated result, ask for the original paper and the section that supports the specific claim.
Customer surveys answer a narrower question
A survey can report what participating customers said. Without an appropriate comparison, it cannot determine how much change was caused by treatment. People may also change exercise, diet, sleep routines or other medication during the same period.
AgelessRx labels its displayed injection results as customer-reported data. That disclosure matters: a reader should assess those figures as survey findings, not as a randomized trial. Ask who was invited, who responded, what question was asked, and whether people who stopped treatment were included.
Evidence must follow the formulation
Do not assume a finding transfers from an injection to a lozenge or nasal preparation. Likewise, research on one medication does not establish another medication’s outcomes. Ivím’s product page includes a note about studies of GLP-1 treatments; those are not studies of sermorelin.
FDA also distinguishes compounded preparations from approved drugs: compounded drugs do not undergo the agency’s premarket review for safety, effectiveness and quality. A historical approval or a pharmacy credential should not be presented as approval of a current compounded formulation.
Turn uncertainty into useful questions
Ask the treating clinician what evidence supports the particular use, how benefit would be measured, what risks matter for your history, and what would lead to stopping or changing treatment. Discuss alternatives and the option of not starting medication.
Uncertainty should stay visible. It need not be filled with an invented score, a guaranteed result or a confident timeline. Our sermorelin evidence overview and safety guide offer further context.
Sources & further reading
Sources reviewed October 2026. Provider prices and terms may change.
- Endocrine Society: Hormones and Aging scientific statement
- FDA: Understanding the risks of compounded drugs
- AgelessRx website
- Ivím Health website